Molecularly Targeted Cancer Medications and Kidney Health
In this cohort study of patients treated with molecularly targeted anticancer medications associated with an acute rise in sCr, we observed higher incidence and relative rate for kidney dysfunction among treated patients, compared with matched cancer-free patients.
Authors
- Jin Long (ORCID: https://orcid.org/0000-0002-6225-727X)
- Ali Raza Khaki (ORCID: https://orcid.org/0000-0002-4655-4426)
- Heather A. Wakelee (ORCID: https://orcid.org/0000-0003-1136-980X)
- Mary Beth Leonard (ORCID: https://orcid.org/0000-0002-8972-6582)
- Shuchi Anand (ORCID: https://orcid.org/0000-0002-9892-8477)
- Fauzia Riaz (ORCID: https://orcid.org/0000-0002-6267-3839)
- Susan Ziolkowski (ORCID: https://orcid.org/0000-0002-0785-598X)
- Yutong Zhong (ORCID: https://orcid.org/0000-0001-9349-9258)
- Sunil Reddy
- Hannah Morgan‐Cooper
Institutions
- Stanford Health Care (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.41221
- Citations
- 2
- Primary Topic
- Chemotherapy-induced organ toxicity mitigation
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Helsinn
- Seagen
- National Institutes of Health
- Genentech
- Chugai Pharmaceutical
- National Institute of Diabetes and Digestive and Kidney Diseases
- Daiichi Sankyo Europe